Skip to main content

Table 1 Clinicopathological demographics of patients treated surgically for RCC with vena caval tumour thrombus

From: Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically

CharacteristicsPure RCC (n = 97)RCC with sarcomatoid and/or rhabdoid differentiation (n = 28)p
Age (years), median (IQR)60 (53–67)55 (52–63)0.205
Gender, n (%)  0.614
 Male68 (70.1)21 (75.0)
 Female29 (29.9)7 (25.0)
Tumour side, n (%)  0.510
 Left25 (25.8)9 (32.1)
 Right72 (74.2)19 (67.9)
Tumour size (cm), mean ± SD8.5 ± 3.210.4 ± 4.10.012
Thrombus level (Mayo), n (%)  0.790
0.038
0.319
 I29 (29.9)9 (32.1)
 II40 (41.2)9 (32.1)
 III19 (19.6)6 (21.4)
 IV9 (9.3)4 (14.3)
Blood transfusion (cc), median (IQR)400 (0–2000)1600 (400–3200)
Tumour stage, n (%)  
 T3b84 (86.6)21 (75.0)
 T3c9 (9.3)4 (14.3)
 T44 (4.1)3 (10.7)
Nodal status, n (%)  1.000
 N0/Nx88 (90.7)26 (92.9)
 N+9 (9.3)2 (7.1)
Metastatic status, n (%)  0.060
 M076 (78.4)17 (60.7)
 M121 (21.6)11 (39.3)
Metastatic sites, n (%)  0.701
 Lung16 (64.0)8 (57.1)
 Bone6 (24.0)5 (35.7)
 Liver3 (12.0)1 (7.1)
Histologic subtype, n (%)  0.454
 Clear cell RCC77 (79.4)24 (85.7)
 Non-clear cell RCC20 (20.6)4 (14.3)
Fuhrman grade, n (%) (n = 120)  0.018
 1–238 (40.4)4 (15.4)
 3–456 (59.6)22 (84.6)
Tumour necrosis, n (%)  0.015
 Absent53 (54.6)8 (28.6)
 Present44 (45.4)20 (71.4)
Adjuvant target therapy38(39.2)11(39.3)0.992
  1. RCC renal cell carcinoma, IQR interquartile range, SD standard deviation